Evidence map›Paper›PMID 38904040›Full record

ArticleFrontiers in endocrinology2024

Association between cathepsins and benign prostate diseases: a bidirectional two-sample Mendelian randomization study.

Hongliang Cao, Bin Liu, Kejian Gong, Hao Wu, Yishu Wang, Haiyang Zhang, Chengdong Shi, Pengyu Wang, Hao Du, Honglan Zhou and 1 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongliang CaoDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Bin LiuDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Kejian GongDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China.
Hao WuDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Yishu WangKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China.
Haiyang ZhangDepartment of Prosthodontics, Hospital of Stomatology, Jilin University, Changchun, China.
Chengdong ShiDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Pengyu WangDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Hao DuDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Honglan ZhouDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.
Song WangDepartment of Urology II, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The relationship between cathepsins and prostate cancer (PCa) has been reported. However, there is a lack of research on cathepsins and benign prostate diseases (BPDs). This study investigated the potential genetic link between cathepsins and BPDs through the utilization of Mendelian randomization (MR) analysis to determine if a causal relationship exists. Methods: Publicly accessible summary statistics on BPDs were obtained from FinnGen Biobank. The data comprised 149,363 individuals, with 30,066 cases and 119,297 controls for BPH, and 123,057 individuals, with 3,760 cases and 119,297 controls for prostatitis. The IEU OpenGWAS provided the Genome-wide association data on ten cathepsins. To evaluate the causal relationship between BPDs and cathepsins, five distinct MR analyses were employed, with the primary method being the inverse variance weighted (IVW) approach. Additionally, sensitivity analyses were conducted to examine the horizontal pleiotropy and heterogeneity of the findings. Results: The examination of IVW MR findings showed that cathepsin O had a beneficial effect on BPH (IVW OR=0.94, 95% CI 0.89-0.98, P=0.0055), while cathepsin X posed a threat to prostatitis (IVW OR=1.08, 95% CI 1.00-1.16, P=0.047). Through reverse MR analysis, it was revealed that prostatitis had an adverse impact on cathepsin V (IVW OR=0.89, 95% CI 0.80-0.99, P=0.035), while no favorable association was observed between BPH and cathepsins. The results obtained from MR-Egger, weighted median, simple mode, and weighted mode methods were consistent with the findings of the IVW approach. Based on sensitivity analyses, heterogeneity, and horizontal pleiotropy are unlikely to distort the results. Conclusion: This study offers the initial evidence of a genetic causal link between cathepsins and BPDs. Our findings revealed that cathepsin O was beneficial in preventing BPH, whereas cathepsin X posed a potential threat to prostatitis. Additionally, prostatitis negatively affected cathepsin V level. These three cathepsins could be targets of diagnosis and treatment for BPDs, which need further research.

Indexed as

CathepsinsGenome-Wide Association StudyMendelian Randomization AnalysisProstatic HyperplasiaCase-Control StudiesGenetic Predisposition to DiseaseHumansMalePolymorphism, Single NucleotideProstatic DiseasesProstatic NeoplasmsProstatitisCathepsinsbenign prostate diseasesbenign prostatic hyperplasia (BPH)bi-directional causal effectscathepsinsMendelian randomization

Identifiers

PMID38904040
PMCPMC11188316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.